Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors HEMATOLOGICAL ONCOLOGY 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice ANNALS OF HEMATOLOGY 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice ANNALS OF HEMATOLOGY 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart HEMATOLOGICAL ONCOLOGY 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention INTERNATIONAL JOURNAL OF CARDIOLOGY 2019
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative AMERICAN JOURNAL OF HEMATOLOGY 2019
Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib HEMATOLOGICAL ONCOLOGY 2019
Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience BLOOD 2019
Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study BLOOD 2019
Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial BLOOD 2019
Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study BLOOD 2019
Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial BLOOD 2019
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial BLOOD 2019
Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors BLOOD 2019
Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement BLOOD 2019
Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence BLOOD 2019
Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study BLOOD 2019

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma